These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24699530)

  • 21. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
    Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
    J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
    Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
    Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 24. Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.
    Joshi T; Elias D; Stenvang J; Alves CL; Teng F; Lyng MB; Lykkesfeldt AE; Brünner N; Wang J; Gupta R; Workman CT; Ditzel HJ
    Oncotarget; 2016 Aug; 7(35):57239-57253. PubMed ID: 27528030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Jan R; Huang M; Lewis-Wambi J
    Breast Cancer Res; 2012 Nov; 14(6):R146. PubMed ID: 23151593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linking short tandem repeat polymorphisms with cytosine modifications in human lymphoblastoid cell lines.
    Zhang Z; Zheng Y; Zhang X; Liu C; Joyce BT; Kibbe WA; Hou L; Zhang W
    Hum Genet; 2016 Feb; 135(2):223-32. PubMed ID: 26714498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
    Kiyotani K; Mushiroda T; Imamura CK; Hosono N; Tsunoda T; Kubo M; Tanigawara Y; Flockhart DA; Desta Z; Skaar TC; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
    J Clin Oncol; 2010 Mar; 28(8):1287-93. PubMed ID: 20124171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans.
    Huang RS; Duan S; Kistner EO; Hartford CM; Dolan ME
    Mol Cancer Ther; 2008 Sep; 7(9):3038-46. PubMed ID: 18765826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
    Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
    J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.
    Hennig EE; Piatkowska M; Karczmarski J; Goryca K; Brewczynska E; Jazwiec R; Kluska A; Omiotek R; Paziewska A; Dadlez M; Ostrowski J
    BMC Cancer; 2015 Aug; 15():570. PubMed ID: 26232141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. miR-451a Inhibited Cell Proliferation and Enhanced Tamoxifen Sensitive in Breast Cancer via Macrophage Migration Inhibitory Factor.
    Liu Z; Miao T; Feng T; Jiang Z; Li M; Zhou L; Li H
    Biomed Res Int; 2015; 2015():207684. PubMed ID: 26161389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Let-7i reduces chemotherapy resistance in breast cancer cells through down-regulation of K-Ras and Bcl2 expression].
    Qin M; Pu C; Feng G; Zhang J; Zheng R; Liu X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Nov; 35(11):992-999. PubMed ID: 31878995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR‑125a‑5p.
    Liu Y; Li M; Yu H; Piao H
    Int J Mol Med; 2020 Feb; 45(2):497-509. PubMed ID: 31894257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
    Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
    Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.
    Zhang HY; Liang F; Zhang JW; Wang F; Wang L; Kang XG
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):327-337. PubMed ID: 28063065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
    Li X; Wu Y; Liu A; Tang X
    Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients.
    Sanchez-Spitman AB; Böhringer S; Dezentjé VO; Gelderblom H; Swen JJ; Guchelaar HJ
    Clin Pharmacol Ther; 2024 Jul; 116(1):155-164. PubMed ID: 38501904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer.
    Han X; Li Q; Liu C; Wang C; Li Y
    J Cell Biochem; 2019 Aug; 120(8):12966-12976. PubMed ID: 31001849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Tan S; Ding K; Chong QY; Zhao J; Liu Y; Shao Y; Zhang Y; Yu Q; Xiong Z; Zhang W; Zhang M; Li G; Li X; Kong X; Ahmad A; Wu Z; Wu Q; Zhao X; Lobie PE; Zhu T
    J Biol Chem; 2017 Aug; 292(33):13551-13564. PubMed ID: 28637868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.